Stocks making the biggest moves premarket: AstraZeneca, PepsiCo, Salesforce, Levi & more
Premarket movers included AstraZeneca, down 8% after its heart disease drug Wainua missed a late-stage trial target. PepsiCo fell 1% after Q2 adjusted EPS of $2.20 missed $2.21 consensus, while revenue beat. Salesforce and Stellantis slid on downgrades. Levi dropped on weaker Q3 guidance. AZZ rose on earnings and revenue beats; Cerebras gained on European expansion; Costco fell on slower June comps.
How this was made
The 30-second read
Why it matters
The article provides concrete, decision-relevant datapoints (trial miss, EPS/revenue vs consensus, guidance range vs consensus, and named analyst downgrades) that can drive immediate positioning and risk management.
Market read
Actionable for traders because it ties each named mover to a specific, quantified catalyst (trial outcome, consensus comparisons, guidance range, or named downgrade).
What to watch
For guidance and trial outcomes, traders may need follow-up details (trial endpoints, management commentary, and any revised outlook) that are not included in this wrap.
Background
This is a multi-stock premarket movers wrap summarizing specific catalysts: a late-stage trial miss, earnings beats/misses, analyst downgrades, and guidance deceleration.
Ticker impact
AstraZeneca tumbled 8% premarket after its heart disease drug Wainua failed to meet a late-stage clinical trial target.
Further downside pressure possible until trial details and next steps are clarified.
The article cites a late-stage miss tied to a specific product, which typically increases probability of setbacks and delays.
PepsiCo shares fell 1% premarket after Q2 adjusted EPS missed by $0.01 while revenue beat consensus.
Choppy trading likely as investors weigh revenue beat versus EPS miss.
The article provides both the miss and beat versus consensus, but no guidance change or margin detail.
Salesforce dropped 4% premarket after KeyBanc downgraded it to sector weight, citing limited evidence of future upside.
Near-term underperformance risk versus peers until new catalysts emerge.
The downgrade thesis is described, but the article does not include new Salesforce fundamentals or updated targets.
Stellantis slid 2% premarket following a JPMorgan downgrade to neutral, saying the turnaround benefits need 14 months.
Likely continued weakness or muted rebounds until investors see progress on turnaround milestones.
The article provides a specific turnaround timeline, but no new company-specific operational data.
Levi Strauss dropped 4% premarket after issuing third-quarter guidance with EPS of 34 to 36 cents versus 38 cents expected.
Further downside possible if investors extrapolate weaker demand or margins into 3Q.
The article includes explicit guidance ranges and the consensus comparison, which is actionable for near-term positioning.
AZZ jumped 6% premarket after reporting EPS of $1.85 and revenue of $448.5 million, both above consensus.
Upside continuation possible if investors treat the beat as evidence of improving execution.
The article provides both EPS and revenue beats versus FactSet, which typically supports a favorable repricing.
Costco fell nearly 2% premarket after reporting June comparable sales growth of 8.8%, down from 12.5% in May.
Range-bound to slightly lower until the market gains confidence the deceleration is temporary.
The article provides the deceleration math but no commentary on pricing, traffic, or guidance.
Market effects
Clinical-trial failure risk hits biopharma sentiment; guidance misses and downgrades pressure software and consumer discretionary read-through; industrial/AI infrastructure beats support selective risk appetite.
Limited explicit regional effects beyond US premarket moves; Stellantis adds European auto sentiment via US-listed analyst action.
AI infrastructure expansion narrative (Cerebras) can reinforce global capex expectations for data center buildouts.
Counterpoint
Some moves may be overextended for premarket, especially where the article cites small EPS misses or analyst downgrades without new company fundamentals.
Key entities
- companyAstraZeneca
Wainua failed to meet a late-stage clinical trial target, triggering an 8% premarket drop.
- companyPepsiCo
Q2 adjusted EPS missed slightly while revenue beat, leading to a 1% premarket decline.
- companySalesforce
KeyBanc downgraded to sector weight, citing limited evidence of future upside, pushing shares down 4% premarket.
- companyStellantis
JPMorgan downgraded to neutral, saying turnaround benefits take 14 months, with shares down 2% premarket.
- companyLevi Strauss
Third-quarter EPS guidance (34 to 36 cents) came in below the 38-cent expectation, shares down 4% premarket.
